Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.00 -4.65% 205.00 200.00 210.00 213.00 205.00 213.00 22,594 10:25:34
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 74.6 15.2 17.6 11.6 138

Eco Animal Health Share Discussion Threads

Showing 426 to 450 of 1125 messages
Chat Pages: Latest  21  20  19  18  17  16  15  14  13  12  11  10  Older
DateSubjectAuthorDiscuss
13/12/2013
11:53
http://www.bbc.co.uk/news/world-us-canada-25340995 going way over my head this, but i sense that this has to be good for Eco and Aivlosin in the US interested to hear what more informed people think! smell
smelleroo
13/12/2013
10:00
AD I can't post a stockpedia chart anymore which would be my preference so it'll have to be the inferior advfn chart. free stock charts from uk.advfn.com The double bottom is fine but it's trended down below the 21 day EMA for some time and although it gapped up and broke through before it didn't hold. The MACD and Directional index are positive too, nevertheless i'd need confirmation with this break through, so i figure a move to around 230p above the 126 day EMA would be sufficient. At this point i'd expect the trend to reverse and the share price to be above 21 day EMA and bounce off it on the dips. The problem with gaps is they tend to get filled as happened with the last breakout. Woody
woodcutter
12/12/2013
13:38
Interesting analysis WC. I think the one product concern is the key risk for EAH which is why I think the duration of the patent is key (something I have never got to the bottom of). For me the difficult thing to predict is the increase in revenue from the new approvals particularly North America & Russia. I think we could see a step-change in the balance sheet compared to previous years but I wouldn't like to attemp to quantify this. Although technical analysis doesn't readily lend itself to this kind of tightly held AIM share, its an interesting chart and a serious double bottom! Is a recovery to 280 in the mid-term a possibility? I hope so and anything the company can do to big-up its profile with investors would help with this.
audigger
10/12/2013
15:31
been busy with ZYT all morning finally found time to look through the EAH results and it looks like it may just be beginning to look an attractive investment. My previous posts have always been inclined to think it was overvalued by comparison to it's peers but crunching a few numbers and making some assumptions it could now have some attraction after a significant share price fall. H2 revenue last year was 28986K H1 revenue last year was 11445K That's an increase of 153% Assuming similar this year, not unreasonable as their market presence has grown. would give annual revenue of around £38743K gross margin consistent around 45% so GP around £17.4m H2 admin last year £6802K H1 admin last year £3167K Overheads in H2 last year increased 114% over H1 so some decent operational gearing there, 153% revenue increase for 114% ohead. Assuming similar for H2 this year So annual overheads at H2 around £8.6m EBITDA £8.8m shares in issue 62.46m (average will be less than this due to fund raising mid year) adjusted (tax out but DA added back) eps roughly 11p EBITDA £8.8m IDA roughly £2.7m pat £4.8m eps 7.7p It looks attractive on a EBIDA per of 19 and is now in line with others in the sector and a major holding of mine like ANP which has closed the gap. My only concerns are too much reliance on one product unlike ANP. If this gets superceeded then there's a massive change in revenue etc. My other concern is can this rate of growth be replicated and for how long. Woody post note: balance sheet is heavily weighted with intangibles too hence the large amortisation, nevertheless the current and acid ratios are very comfortable. I figure the share price is currently up with events.
woodcutter
10/12/2013
07:29
As I have previously stated my belief is that 2014 will be a transformational year for the company with a step increase in sales and new registrations.
ltinvestor
10/12/2013
07:22
And indeed they have been! All looks very good especially as the main new revenue streams have yet to cone full on-board. I won't attempt to predict the share price move today as I frequently get magnitude of change wrong.
audigger
09/12/2013
15:18
I believe results will be released tomorrow. Regards, GHF
glasshalfull
09/12/2013
11:13
Expecting results this week and a very positive update.
ltinvestor
02/12/2013
15:42
Half yearly results next week.
ltinvestor
02/12/2013
14:20
The door opens to yet another income stream. Its all set-up for 2014-2015 to be a record year for the company
audigger
27/11/2013
12:39
company moving fast in the right direction - see this news out in the US the other day. am sure share price will re-rate in due course, probably with the results in the next week or so.... Pharmgate Receives Regulatory Approval for Deracin® 22% Granular, in Canada Pharmgate LLC of Ramsey, NJ, announces the approval of its flagship product, Deracin® 22% Granular Premix containing 22% chlortetracycline, by the Veterinary Drugs Directorate of Health Canada. As the majority owned U.S. subsidiary of Jinhe Biotechnology, the largest manufacturer of chlortetracycline in the world, Pharmgate will become a significant supplier of branded chlortetracycline products in Canada. Pharmgate LLC of Ramsey, NJ, announces the approval of its flagship product, Deracin® 22% Granular Premix containing 22% chlortetracycline, by the Veterinary Drugs Directorate of Health Canada. As the majority-owned U.S. subsidiary of Jinhe Biotechnology, the largest manufacturer of chlortetracycline in the world, Pharmgate will become a significant supplier of branded chlortetracycline products in Canada. This generic approval carries all important label claims for the drug across livestock and poultry species. Deracin 22% Granular Premix is a high-quality, free-flowing, and dust-free granule that is manufactured and formulated in the plant that has enjoyed a 20 year history of supplying FDA-compliant products. The product is supplied in 25kg bags and will be made available to feedmills and livestock producers in the coming months. It will be marketed by Pharmgate Animal Health, Pharmgate's marketing joint venture in North America, alongside its first product offering, Aivlosin® (tylvalosin) Water Soluble Granules, which has received considerable support from the livestock community since its launch last year. Colin Gray, CEO of Pharmgate commented, "This is another important step in the evolution of Jinhe/Pharmgate from the largest global supplier of high quality CTC to a fully integrated and recognized animal health company. We, in company with our partners and in utilizing Pharmgate's significant supply chain, regulatory and marketing expertise look forward to building on this success in adding future complementary products over the next several years." hxxp://nationalhogfarmer.com/pharmgate-receives-regulatory-approval-deracin-22-granular-canada
smelleroo
21/11/2013
10:31
Wouldn't be too concerned but all will be revealed shortly with the half yearly results in a couple of weeks time.
ltinvestor
21/11/2013
09:45
Getting a bit worrying is this latest drop.....good buying opportunity though!
audigger
06/11/2013
11:31
Good article LP. To have China as a key market in addition to US, EU & Russia menas the potential revenues for Aivlosin must be huge. Also interesting to see the premium product positioning in the US which will hopefully nean higher margins
audigger
06/11/2013
08:40
Chinese tastes bode well for ECO Animal By Philip Whiterow It's not only metals and oil that Chinese firms are tapping into as sources of supply. Smithfield Foods, America's largest pork supplier, has just been taken over by Shuanghui, its equivalent in China, in a US$4.7bn deal. http://tinyurl.com/okdm5a6
lucky_punter
29/10/2013
20:44
Great looking chart!
ltinvestor
28/10/2013
13:32
Good timing IT, especially with another indication now coming online in the EU
audigger
22/10/2013
07:27
Added yesterday as the US was always going to be the largest market for Aivlosin and it looks like this is the case.Substantial sales here will be rapidly reflected in the bottom line imho.Well below the radar at the moment but that should change in 2014.
ltinvestor
16/10/2013
16:47
Almost hit 1.94 to buy. Hopefully that will be the floor from which the share price will recover
audigger
04/10/2013
16:40
Yes I think the way the directors have dealt with this is mindful of the impact on the share price I have no doubt the the next set of results will be very impressive. The unknown is how long it will take the share price to respond accordingly. I'm sure Mr Lawrence will be very well rewarded when the sell the Co. Clearly this was the right course of action so I have no problem with it. If I had spare cash right now I would add once the share price hits 194.
audigger
04/10/2013
15:08
money has been raised for VERY good reasons! Peter Lawrence has also bought more shares, and will now hold over 18% of EAH
smelleroo
04/10/2013
14:32
194p here we come!
audigger
03/10/2013
10:50
Blimey, I didn't see this coming! Explains the long slow drift of recent months. Clealry the underying business is doing well, so one has to hope this is a one-off. Arguably a good opportunity to add, but this is looking longer & longer term in terms of the pot of gold at the end of the rainbow. As previously noted on this board, it does make you wonder about the buisness model and the cut in margin taken along the distribution chain.
audigger
10/9/2013
20:34
Once the US market kicks-in then the future revenue & profit will increase significantly. I expect 2014-2015 revenue & profit to be a step-change from where we are today.
audigger
10/9/2013
00:40
I have reread the year end report and am again encouraged by their future prospects. all regions did well last year except s. America but apparently that came good in the last two months. what we need is for the chaimans encouraging remarks for the future to be turned in sustainable, growing revenues and profits.
cnx
Chat Pages: Latest  21  20  19  18  17  16  15  14  13  12  11  10  Older
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200229 01:24:41